What to Expect From AbbVie's Next Quarterly Earnings Report

Core Insights - AbbVie Inc. is a global pharmaceutical company with a market cap of $403.8 billion, focusing on various health issues across multiple therapeutic areas [1] Financial Performance - Analysts expect AbbVie to report a profit of $3.37 per share for Q4 2025, a 56% increase from $2.16 per share in the same quarter last year [2] - For the full year, AbbVie is projected to report an EPS of $10.65, reflecting a 5.2% increase from $10.12 in fiscal 2024, with an anticipated rise to $14.42 in fiscal 2026, representing a 35.4% year-over-year growth [3] Stock Performance - AbbVie stock has outperformed the S&P 500 Index, gaining 29.7% over the past 52 weeks compared to the index's 16.4% increase [4] - The stock also surpassed the Health Care Select Sector SPDR Fund's 12.8% returns during the same period [4] Growth Drivers - The company's strong performance is attributed to the success of its drugs Skyrizi and Rinvoq, double-digit growth in neuroscience, and strategic acquisitions such as Gilgamesh and Capstan Therapeutics [5] - AbbVie is expanding its manufacturing capabilities with a $195 million investment in North Chicago and a $70 million expansion in Worcester, while advancing pipeline programs for alopecia areata, vitiligo, and Parkinson's disease [5] Recent Earnings Report - On October 31, AbbVie reported a Q3 adjusted EPS of $1.86, exceeding Wall Street's expectations of $1.77, with revenue of $15.8 billion, also surpassing the forecast of $15.6 billion [6] - The company expects its full-year adjusted EPS to be in the range of $10.61 to $10.65 [6] Analyst Ratings - The consensus opinion on AbbVie stock is moderately bullish, with a "Moderate Buy" rating from 28 analysts; 16 recommend a "Strong Buy," 1 a "Moderate Buy," and 11 a "Hold" [7] - AbbVie's average analyst price target is $245.81, indicating a potential upside of 7.6% from current levels [7]